75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - Condensed Balance Sheets (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - Condensed Statements of Operations (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - Condensed Statements of Comprehensive Loss (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - Condensed Statements of Stockholders' Deficit (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - Condensed Statements of Stockholders' Deficit (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75070 - Statement - Condensed Statements of Cash Flows (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Organization and Principal Activities
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Cash Equivalents and Marketable Securities
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Collaboration and License Agreements and Supply Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Accrued Expenses and Other Current Liabilities
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Segment Reporting
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Restructuring and Related Costs
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Stockholders' Equity
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Net Loss Per Share
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Defined Contribution Plan
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Subsequent Event
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Fair Value Measurements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Cash Equivalents and Marketable Securities (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Collaboration and License Agreements and Supply Agreements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Commitments and Contingencies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Segment Reporting (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Restructuring and Related Costs (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Stockholders' Equity (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Net Loss Per Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Organization and Principal Activities - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Fair Value Measurements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Collaboration and License Agreements and Supply Agreements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Collaboration and License Agreements and Supply Agreements - Additional Information (Details) [Default]
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Collaboration and License Agreements and Supply Agreements - Summary of Deferred Revenue Balance (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Collaboration and License Agreements and Supply Agreements - Performance Obligations - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Collaboration and License Agreements and Supply Agreements - Performance Obligations - Additional Information (Details) [Default]
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Commitments and Contingencies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - Segment Reporting - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Segment Reporting - Summary of Segment Net Loss Including Significant Segment Expenses (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - Restructuring and Related Costs - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - Restructuring and Related Costs - Summary of Restructuring and Related Costs (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - Restructuring and Related Costs - Summary of Severance and Other Termination Benefit Expense and Reconciliation of Such Liability (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - Stockholders' Equity - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996005 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Option Activity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996015 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Schedule of Employee Stock Options Valuation (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996025 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Status and Activity of Non-vested RSUs (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996035 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Schedule of Fair Value of ESPP Shares Using Option Pricing Model (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996045 - Disclosure - Equity Incentive Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996055 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of the Status of Call Options (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996065 - Disclosure - Net Loss Per Share - Summary of Computation of Company's Basic and Diluted Net Loss Per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996075 - Disclosure - Net Loss Per Share - Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996085 - Disclosure - Defined Contribution Plan - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Vested and released
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Segments [Domain]
Liability balance
Restructuring Reserve
Restructuring Reserve, Total
Liability balance
Transaction price.
Transaction price
Transaction Price
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Preferred Stock, Shares Issued, Total
Preferred stock, shares issued
Preferred Stock, Shares Issued
Statement of Financial Position Location, Balance [Domain]
Increase (Decrease) in Accounts Payable, Total
Accounts payable
Increase (Decrease) in Accounts Payable
Adjustment Net Of Issuance Costs
Adjustment net of issuance costs.
Plan Name
Plan Name [Axis]
Deferred royalty obligation related to the sale of future royalties.
Deferred Royalty Obligation related to the Sale of Future Royalties [Text Block]
Deferred Royalty Obligation related to the Sale of Future Royalties
Entity Current Reporting Status
Entity Current Reporting Status
Ipsen Agreements [Member]
Ipsen Agreements.
Ipsen Agreements
Operating expenses
Operating Expenses [Abstract]
Level 2
Fair Value, Inputs, Level 2 [Member]
Underwritten Public Offering [Member]
Underwritten public offering.
Underwritten Public Offering
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Common stock, shares authorized
Common Stock, Shares Authorized
Product and Service
Product and Service [Axis]
Document Fiscal Period Focus
Document Fiscal Period Focus
Entity Shell Company
Entity Shell Company
Cash and Cash Equivalents, at Carrying Value, Ending Balance
Cash and Cash Equivalents, at Carrying Value, Beginning Balance
Cash and Cash Equivalents, at Carrying Value, Total
Less amounts classified as cash equivalents, Amortized Cost Basis
Cash and cash equivalents
Cash and Cash Equivalent
Less amounts classified as cash equivalents, Amortized Cost Basis
Non-cash interest expense related to the sale of future royalties.
Non-cash Interest Expense Related To The Sale Of Future Royalties
Non-cash interest expense related to the sale of future royalties
Non-cash interest expense related to the sale of future royalties
2004 Plan, 2018 Plan and 2021 Plan
Two Thousand Four Plan Two Thousand Eighteen Equity Incentive Plan And Two Thousand Twenty One Equity Inducement Plan [Member]
Two thousand four plan two thousand eighteen equity incentive plan and two thousand twenty one equity inducement plan.
Common Stock, Shares, Issued, Total
Common Stock, Shares, Issued
Common stock, shares issued
Common Stock, Shares, Issued
Asset Class
Asset Class [Domain]
Statement [Table]
Statement [Table]
Restricted cash
Restricted Cash, Noncurrent
2015 License Agreement
Two thousand fifteen license agreement.
Two Thousand Fifteen License Agreement [Member]
Statement [Line Items]
Statement [Line Items]
Warrants to Purchase Common Stock
Warrant [Member]
Entity Filer Category
Entity Filer Category
Number of shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Liabilities and Equity
Total Liabilities and Stockholders' Deficit
Payables and Accruals [Abstract]
Increase (Decrease) in Employee Related Liabilities, Total
Accrued compensation
Increase (Decrease) in Employee Related Liabilities
Payments to Acquire Marketable Securities, Total
Purchases of marketable securities
Payments to Acquire Marketable Securities
Stock options exercisable, Weighted - Average Exercise Price, Exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Restructuring Type [Axis]
Long-Lived Tangible Asset
Long-Lived Tangible Asset [Axis]
Severance Costs
Severance and benefits expense
Revenue interest percentage.
Revenue Interest Percentage
Revenue interest percentage
Prepaid Expenses and Other Current Assets [Member]
Prepaid Expenses and Other Current Assets
Restructuring and Related Costs [Table Text Block]
Summary of Restructuring and Related Costs
Less amounts classified as cash equivalents, Fair Value
Cash and Cash Equivalents, Fair Value Disclosure
Other Noncash Income (Expense), Total
Other
Other Noncash Income (Expense)
Amortization of issuance costs.
Amortization of issuance costs
Stock Options
Geographical
Geographical [Domain]
Cash, Cash Equivalents and Restricted Cash
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Asset-Backed Securities [Member]
Asset-backed Securities
BMS Agreement and the 2018 BMS Master Services Agreement
BMS Agreement And Two Thousand Eighteen BMS Master Services Agreement [Member]
BMS agreement and two thousand eighteen BMS master services agreement.
Stock Issued During Period Value Through The Public Offering
Stock issued during period value through the public offering.
Issuance of common stock in connection with public offering, net of issuance costs
Royalty obligation.
Royalty Obligation [Table Text Block]
Schedule of Royalty Obligation transaction
Accounts Receivable, Allowance for Credit Loss, Ending Balance
Accounts Receivable, Allowance for Credit Loss, Beginning Balance
Accounts receivable, reserve for credit losses
Accounts Receivable, Allowance for Credit Loss
Additional Paid in Capital, Common Stock, Ending Balance
Additional Paid in Capital, Common Stock, Beginning Balance
Additional paid-in-capital
Additional Paid in Capital, Common Stock
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation
Stock transactions associated with taxes withheld on restricted stock units
Related Party
Related Party [Member]
Remaining Shares Reserved for Issuance under 2018 Equity Incentive Plan and 2021 Equity Inducement Plan
Remaining shares reserved for issuance under 2018 Equity Incentive Plan and 2021 Equity Inducement Plan
2018 Equity Incentive Plan and 2021 Equity Inducement Plan
Two thousand eighteen equity incentive plan and two thousand twenty one equity inducement plan.
Defined Contribution Plan
Defined Contribution Plan [Text Block]
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Sales of marketable securities
Proceeds From Sales Of Marketable Securities
Proceeds from sales of marketable securities.
Total options granted
Share-based compensation arrangement by share-based payment award options, shares granted
Granted, Shares
Summary of Computation of Company's Basic and Diluted Net Loss Per Share
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Preclinical research and clinical development expenses
Preclinical research and clinical development expenses
Preclinical research and clinical development expenses.
Contingent payment recognized as deferred revenue
Contingent Payment Recognized As Deferred Revenue
Contingent payment recognized as deferred revenue.
Investment, Name [Axis]
Net loss per share, basic
Net loss per share, basic
Earnings Per Share, Basic, Total
Net (loss) income per share, basic
Tasly Biopharmaceuticals Co. Ltd [Member]
Tasly Biopharmaceuticals Co. Ltd.
Tasly Biopharmaceuticals Co., Ltd.
Options vested and outstanding
Stock options outstanding, Beginning Balance, Shares
Stock options outstanding, Ending Balance, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Total current liabilities
Liabilities, Current
Accounts receivable
Increase (Decrease) in Accounts Receivable
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Interest and other income (expense), net
Interest and Other Income (Expense), Net
Interest and other income (expense), net.
Consolidation Items [Domain]
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent
Restructuring plan, percentage of workforce reduction
Equity, Attributable to Parent [Abstract]
Stockholders' deficit :
Entity Small Business
Entity Small Business
Retained Earnings (Accumulated Deficit), Ending Balance
Retained Earnings (Accumulated Deficit), Beginning Balance
Retained Earnings (Accumulated Deficit), Total
Accumulated deficit
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Reversal of common stock under Employee Stock Purchase Plan ,Shares
Reversal Of Common Stock Shares Under Employee Stock Purchase Plan
Reversal of common stock shares under employee stock purchase plan.
Reversal of common stock under Employee Stock Purchase Plan ,Shares
Organization and Principal Activities
Nature of Operations [Text Block]
Canceled and forfeited, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Sale of Stock, Price Per Share
Offering price
Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation
Share-Based Payment Arrangement [Text Block]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stockholders Equity [Table]
Stockholders Equity [Table]
Stockholders equity.
Common Stock Options Issued and Outstanding
Common Stock Option Issued And Outstanding [Member]
Common stock option issued and outstanding.
Maturities of marketable securities
Proceeds From Maturities Of Marketable Securities
Proceeds from maturities of marketable securities.
Upfront payment received
Upfront Payment Received
Upfront payment received.
Contract with Customer, Liability, Total
Deferred revenue
Deferred revenue
Deferred revenue
Contract with Customer, Liability
Amendment Flag
Amendment Flag
Product and Service
Product and Service [Domain]
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Astellas pharma inc. ("Astellas").
Astellas Pharma Inc. ("Astellas") [Member]
Astellas Pharma Inc. ("Astellas")
Annual increase period of common stock reserved for issuance
Annual Increment Period Of Common Stock Reserved For Issuance
Annual increase period of common stock reserved for issuance.
2020 Merck Master Services Agreement
Two Thousand Twenty Merck Master Services Agreement [Member]
2020 Merck master services agreement.
Liabilities and Equity [Abstract]
Liabilities and Stockholders' Deficit
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Net cash used in operating activities
Increase (Decrease) in Operating Lease Liability
Operating lease liability
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description
Common Stock Options Issued and Outstanding
Common Stock
Common Stock [Member]
Call Option Plan
Call Option Plan [Member]
Call option plan.
Weighted - Average Exercise Price, Granted
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Entity Address, Address Line One
Entity Address, Address Line One
Clinical Trials
Clinical Trials [Member]
Clinical trials.
Schedule of Employee Stock Options Valuation
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
2021 Equity Inducement Plan
Two Thousand Twenty One Equity Inducement Plan Member
Two thousand twenty one equity inducement plan.
Level 2
Fair Value Hierarchy and NAV [Axis]
Earnings Per Share [Abstract]
Supplemental disclosure of cash flow information:
Supplemental Cash Flow Information [Abstract]
Foreign Currency Translation
Foreign Currency Transactions and Translations Policy [Policy Text Block]
Astellas License and Collaboration Agreement
Astellas License and Collaboration Agreement [Member]
Astellas license and collaboration agreement.
Statement of Financial Position Location, Balance [Axis]
Shares to be issued under employee stock purchase plan.
Shares to be Issued Under Employee Stock Purchase Plan
Shares to be issued under employee stock purchase plan [Member]
Operating lease right-of-use assets
Operating Lease, Right-of-Use Asset
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Net unrealized gain (loss) on available-for-sale securities
Document Type
Document Type
Income Taxes Paid, Net, Total
Income Taxes Paid, Net
Income tax paid (refunds received)
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Entity Central Index Key
Entity Central Index Key
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]
Other comprehensive gain (loss):
Restructuring Reserve, Current
Restructuring related accrual
Milestone payment receivable.
Milestone Payment Receivable
Milestone payment receivable
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Net decrease in cash, cash equivalents and restricted cash
Antidilutive securities excluded from computation of net loss per share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Common stock value per share
Common stock, par value
Common Stock, Par or Stated Value Per Share
2019 EMD Serono Supply Agreement
Two Thousand Nineteen E M D Serono Supply Agreements [Member]
2019 EMD Serono supply agreements.
Weighted - Average Remaining Contract Term
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Expected volatility, Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Amortized Cost Basis
Debt Securities, Available-for-Sale, Amortized Cost
Debt Securities, Available-for-sale, Total
Fair Value
Debt Securities, Available-for-Sale
Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table]
Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table]
Schedule of organization consolidation and presentation of financial statements.
Exercised, Shares
Options vested and exercised
Exercise of common stock options, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance
Options unvested and outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares
Amount expected to be incurred in connection with severance
Restructuring and Related Cost, Expected Cost
Restructuring and Related Cost, Expected Cost, Total
Vaxcyte
Vaxcyte, Inc.
Vaxcyte, Inc.
Vaxcyte Agreement
Accrued Liabilities, Current, Total
Accrued compensation
Accrued Liabilities, Current
Other [Member]
Other
Other
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Current Fiscal Year End Date
Current Fiscal Year End Date
Document Quarterly Report
Document Quarterly Report
Ipsen agreement.
Ipsen Agreement [Member]
Ipsen Agreement
California
CALIFORNIA
Blackstone life sciences.
Blackstone Life Sciences [Member]
Blackstone Life Sciences
Headquartered in state
Entity Address, State or Province
Entity Address, State or Province
Non-vested, Beginning Balance
Non-vested, Ending balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Investment, Name [Domain]
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred stock, outstanding
Preferred stock shares outstanding
Preferred Stock, Shares Outstanding
Comprehensive loss
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Unrealized Gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Reserved common stock
Common Stock, Capital Shares Reserved for Future Issuance
Number of target programs
Number Of Target Programs
Number of target programs.
Geographical
Geographical [Axis]
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation
Stock transactions associated with taxes withheld on restricted stock units, Shares
Marketable Securities, Current, Total
Marketable securities
Marketable Securities, Current
Bristol-Myers Squibb Company ("BMS")
Bristol Myers Squibb Company B M S [Member]
Bristol-Myers Squibb Company ("BMS").
Schedule of Stock-Based Compensation Expense Recognized
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Exercise of common stock options
Stock Issued During Period, Value, Stock Options Exercised
Accrued Expenses and Other Current Liabilities
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]
Astellas Agreement and CFE Supply Agreement [Member]
Astellas Agreement and CFE Supply Agreement.
Astellas Agreement and CFE Supply Agreement
Non cash interest expense on deferred royalty obligation.
Non Cash Interest Expense On Deferred Royalty Obligation
Non-cash interest expense on deferred royalty obligation
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Line Items]
Share based compensation arrangement by share based payment award fair value assumptions and methodology.
March and September 2025 Restructuring Plan [Member]
March and September 2025 Restructuring Plan.
March and September 2025 Restructuring Plan
Collaboration and License Agreements and Supply Agreements
Collaboration And License Agreements And Supply Agreements [Text Block]
Collaboration and license agreements and supply agreements.
Other Assets, Noncurrent, Total
Other non-current assets
Other Assets, Noncurrent
Gain (Loss) on Contract Termination
Contract termination and other restructuring costs
Collaboration Agreements And Supply Agreements [Abstract]
Collaboration agreements and supply agreements.
Antidilutive Securities
Antidilutive Securities [Axis]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]
Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'')
Merck K Ga A Darmstadt Germany [Member]
Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name “EMD Serono”).
Related Party Transaction
Related Party Transaction [Axis]
Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to Parent [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Purchases of equipment and leasehold improvements
Payments To Acquire Equipment And Leasehold Improvements
Payments to acquire equipment and leasehold improvements.
Cash and Cash Equivalents
Cash and Cash Equivalents [Domain]
Accrued expenses and other current liabilities
Total accrued expenses and other current liabilities
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities.
Total accrued expenses and other current liabilities
Preferred Stock, Value, Issued, Ending Balance
Preferred Stock, Value, Issued, Beginning Balance
Preferred Stock, Value, Issued, Total
Preferred Stock, Value, Issued
Preferred stock, $0.001 par value - 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Schedule of Accrued Expenses and Other Current Liabilities
Schedule of Accrued Liabilities and Other Liabilities Disclosure, Current [Table Text Block]
Schedule of accrued liabilities and other liabilities disclosure, current.
Stockholders equity.
Stockholders Equity [Line Items]
Stockholders Equity [Line Items]
Minimum
Minimum
Minimum [Member]
Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Financial Instrument
Financial Instrument [Axis]
Current assets:
Assets, Current [Abstract]
Level 3
Fair Value, Inputs, Level 3 [Member]
Segment Reporting [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Fair Value of Financial Assets and Liabilities Measured on Recurring Basis
2018 Equity Incentive Plan
Two Thousand Eighteen Equity Incentive Plan [Member]
Two thousand eighteen equity incentive plan.
Current liabilities:
Liabilities, Current [Abstract]
Financing Component On Unearned Revenue [Member]
Financing component on unearned revenue.
Financing Component on Unearned Revenue
Restructuring and Related Activities Disclosure [Text Block]
Restructuring and Related Costs
Non cash interest expense associated with the sale of future royalties
Non Cash Interest Expense Associated With The Sale of Future Royalties
Non-cash interest expense associated with the sale of future Vaxcyte royalties
Amendment Number Three Two Thousand Fifteen License Agreement.
Amendment Number Three Two Thousand Fifteen License Agreement [Member]
Amendment 3 2015 License Agreement
Common Stock Balance, Shares
Common Stock Balance, Shares
Shares, Outstanding
Marketable Securities
Marketable Securities [Member]
Marketable securities.
Marketable Securities
Accounts Receivable, after Allowance for Credit Loss, Current, Total
Accounts receivable
Accounts Receivable, after Allowance for Credit Loss, Current
Lease renewal term
Lessee, Operating Lease, Renewal Term
Proceeds from employee stock purchase plan
Proceeds from Stock Plans
Commitments and contingencies (Note 6)
Commitments and Contingencies
Reimbursements Charges Related to Negotiated Resolution
Reimbursements charges related to negotiated resolution.
Reimbursements charges related to negotiated resolution
Non-vested, Beginning Balance
Non-vested, Ending balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Organization consolidation and presentation of financial statements line items.
General and Administrative Expense
General and Administrative Expense [Member]
Operating lease liabilities
Operating Lease, Liability
Issuance of common stock in connection with public offering, net of issuance costs, Shares
Stock Issued During Period Shares Through The Public Offering
Stock issued during period shares through the public offering.
Marketable Securities, Noncurrent, Total
Marketable Securities, Noncurrent
Marketable securities, non-current
Long-term marketable securities
Deferred royalty obligation.
Deferred Royalty Obligation [Table]
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]
Summary of Severance and Other Termination Benefit Expense and Reconciliation of Such Liability
Purchases of equipment included in accounts payable and accrued expense
Capital Expenditures Incurred but Not yet Paid
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Restructuring Costs and Asset Impairment Charges [Abstract]
Loss Contingencies [Table]
Loss Contingencies [Table]
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted-average shares used in computing basic net (loss) income per share
Weighted Average Number of Shares Outstanding, Basic
Weighted-average shares used in computing basic net loss per share
Warrants to Purchase Common Stock
Warrants To Purchase Common Stock [Member]
Warrants to purchase common stock.
Aggregate Intrinsic Value, Exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Estimated Service Period
Estimated service period
Estimated service period.
Basis of presentation and use of estimates.
Basis of Presentation and Use of Estimates
Basis Of Presentation And Use Of Estimates Policy Policy [Text Block]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Segments [Axis]
Long-Lived Tangible Asset
Long-Lived Tangible Asset [Domain]
Less amounts classified as cash equivalents, Unrealized Gains
Cash Equivalents Unrealized Gains
Cash equivalents unrealized gains.
Less amounts classified as cash equivalents, Unrealized Gains
Subsequent Event
Subsequent Events [Text Block]
APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total
Stock-based compensation expense
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Accrued expenses and other liabilities
Increase (Decrease) in Accrued Expenses and Other Liabilities
Increase (decrease) in accrued expenses and other liabilities.
Balances
Balances
Equity, Attributable to Parent
Total stockholders' deficit
Preferred stock, par value
Preferred Stock, Par or Stated Value Per Share
Vaxcyte
Vaxcyte.
Vaxcyte [Member]
Statement of Stockholders' Equity [Abstract]
Stock Issued During Period Value Through The Underwritten Offerings
Stock issued during period value through the underwritten offerings.
Issuance of common stock in connection with underwritten offering, net of issuance costs
Type of Restructuring [Domain]
Cash Equivalents
Cash Equivalents [Member]
Additional milestone payment
Additional Milestone Payment
Additional milestone payment.
Fair Value Disclosures [Text Block]
Fair Value Measurements
Contracts Variable Consideration
Contracts variable consideration.
Constrained variable consideration
Adjustments and Reconciling Items
Adjustments and reconciling items.
Adjustments and reconciling items
Date of incorporation
Entity Incorporation, Date of Incorporation
Supplemental disclosure of non-cash investing and financing information:
Noncash Investing and Financing Items [Abstract]
Vaxcyte agreements.
Vaxcyte Agreements [Member]
Vaxcyte Agreements
Severance and Change in Control Plan [Member]
Severance and change in control plan.
CIC Plan
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Plan Name
Plan Name [Domain]
Adjustments and Reconciling Items
Eliminations And Reconciling Items [Member]
Eliminations and reconciling items.
Schedule of Fair Value of ESPP Shares Using Option Pricing Model
Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]
Schedule of Common Stock Reserved for Future Issuance
Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]
Schedule of common stock reserved for future issuance.
Upfront Payment
Upfront Payment [Member]
Upfront payment.
Ipsen Pharma SAS ("Ipsen")
Ipsen Pharma S A S [Member]
Ipsen Pharma S A S.
Deferred Charges, Policy [Policy Text Block]
Deferred Offering Costs
Restructuring Plan [Axis]
Related Party
Related and Nonrelated Parties [Axis]
Leerink Partners LLC and TD Securities (USA) LLC
Leerink Partners LLC and TD Securities (USA) LLC [Member]
Leerink partners LLC and td securities (USA) LLC.
Headquartered in
Entity Address, City or Town
Entity Address, City or Town
Security Exchange Name
Security Exchange Name
Deferred Offering Costs
Deferred offering costs
Counterparty Name
Counterparty Name [Axis]
Loss before provision for income taxes
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Percentage of interest rate amortize liability
Percentage Of Interest Rate Amortize Liability
Percentage of interest rate amortize liability
Antidilutive Securities, Name
Antidilutive Securities, Name [Domain]
Stockholders' Equity Note [Abstract]
Transaction costs incurred.
Transaction costs incurred
Total cash, cash equivalents, and restricted cash shown in the condensed Statements of Cash Flows
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Statistical Measurement
Statistical Measurement [Domain]
Total current assets
Assets, Current
Stock-based compensation expense
Total stock-based compensation expense
Share-Based Payment Arrangement, Expense
Document Period End Date
Document Period End Date
Number of performance obligations
Number Of Performance Obligations
Number of performance obligations.
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Domain]
Defined Contribution Plan, Cost
Contribution expenses
Stock options exercisable, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Statement of Financial Position [Abstract]
Restricted Stock Units
Restricted Stock Units (RSUs) [Member]
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue Recognition
Revenue [Policy Text Block]
Antidilutive Security, Excluded EPS Calculation [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Total liabilities
Liabilities
Financial Instruments
Financial Instruments [Domain]
Restructuring and Related Cost, Incurred Cost
Accrued restructuring-related cost
Financing component associated with program fees.
Financing Component Associated with Program Fees
Financing component associated with program fees
Collaboration and license agreements and supply agreement accruals
Collaboration and License Agreements and Supply Agreement Accruals Current
Collaboration and license agreements and supply agreement accruals current.
Period from issuance date of unaudited interim condensed financial statements
Period From Issuance Of Unaudited Interim Condensed Financial Statements
Period from issuance of unaudited interim condensed financial statements
Shares Reserved for Issuance Under 2018 Employee Stock Purchase Plan
2018 Employee Stock Purchase Plan
Two Thousand Eighteen Employee Stock Purchase Plan [Member]
Two thousand eighteen employee stock purchase plan.
Schedule Of Cash And Cash Equivalents [Table]
Cash and Cash Equivalent [Table]
Weighted-average shares used to compute diluted EPS
Weighted-average shares used in computing diluted net (loss) income per share
Weighted Average Number of Shares Outstanding, Diluted
Weighted-average shares used in computing diluted net loss per share
Entity File Number
Securities Act File Number
Cover [Abstract]
Expected volatility, Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
Investment Income, Nonoperating, Total
Interest income
Investment Income, Nonoperating
Prepaid expenses and other current assets
Prepaid Expense and Other Assets, Current
Canceled and forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Upfront License Fee
Upfront license fee.
Upfront license fee
Maximum number of shares issuable
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Number of operating segments
Number of Operating Segments
Sale of Stock [Domain]
Reimbursements expenses accruals
Reimbursements Expenses Accruals
Reimbursements expenses accruals.
Segment Reporting
Segment Reporting Disclosure [Text Block]
General and Administrative Expense, Total
General and administrative
General and Administrative Expense
Collaboration and License Agreements and Supply Agreements
Collaboration And License Agreements And Supply Agreements [Member]
Collaboration and license agreements and supply agreements.
Less amounts classified as cash equivalents, Unrealized Losses
Cash Equivalents Unrealized Losses
Cash equivalents unrealized losses.
Operating lease expense
Operating Lease, Expense
Restructuring Charges
Restructuring Charges, Total
Expense recognized during the period
Expenses amounted
Recent Accounting Pronouncements Not Yet Adopted
New Accounting Pronouncements, Policy [Policy Text Block]
Schedule of Maturities of Operating Lease Liabilities
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Contract with Customer, Liability, Current
Deferred revenue - current
Deferred royalty obligation.
Deferred Royalty Obligation [Line Items]
Shares vesting period
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Employee Severance [Member]
Employee Severance
Contingent payment.
Contingent Payment
Contingent Payment [Member]
Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate
Maximum Amount Eligible To Receive For Development Regulatory And Commercial Milestones For Each Product Candidate
Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate.
Risk-free interest rate, Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Fair Market Value of Common Stock Issued
Fair market value of common stock issued.
Fair market value of common stock issued
Unrecognized stock-based compensation expense
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
Nonrefundable, non-creditable upfront payment receivable
Nonrefundable Noncreditable Upfront Payment Receivable
Nonrefundable non-creditable upfront payment receivable.
San Carlos Lease
San Carlos Lease [Member]
San carlos lease.
Common Stock, Shares, Outstanding, Ending Balance
Common Stock, Shares, Outstanding, Beginning Balance
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Operating lease liabilities current
Less: current portion
Operating lease liability - current
Operating Lease, Liability, Current
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Depreciation and amortization
Depreciation, Depletion and Amortization, Total
Depreciation, Depletion and Amortization
Revenue, remaining performance obligation, amount
Revenue, Remaining Performance Obligation, Amount
Document Transition Report
Document Transition Report
Facility and maintenance expenses
Facility and maintenance expenses.
Facility and maintenance expenses
Total operating expenses
Operating Expenses
Operating expenses
Research and Development Expense, Total
Research and development
Research and Development Expense
Deferred royalty obligation.
Deferred Royalty Obligation [Abstract]
Statement of Cash Flows [Abstract]
Weighted Average Grant-Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonrefundable, Non-creditable Upfront Fee Payment
Nonrefundable, non-creditable upfront fee payment.
Nonrefundable, non-creditable upfront payment
Stock Issued During Period, Value, New Issues
Issuance of common stock to Ipsen Biopharmaceuticals, Inc. (USA) under the Ipsen Investment Agreement
Summary of Option Activity
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Assets:
Assets, Fair Value Disclosure [Abstract]
Recognition of other-than-temporary impairment
Other Than Temporary Impairment Losses Debt Securities Available For Sale Recognized In Earnings
Other than temporary impairment losses debt securities available for sale recognized in earnings.
Stockholders' Equity
Equity [Text Block]
Net Loss Per Share
Earnings Per Share [Text Block]
Summary of Status and Activity of Non-vested RSUs
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
Net loss
Net loss
Aggregate Intrinsic Value, Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Operating lease cost
Operating Lease, Cost
Business segment [Member]
Business Segment
Business segment [Member]
Expected dividend
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Operating lease payments
Operating Lease, Payments
Assets
Assets [Abstract]
Risk-free interest rate
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Increase (Decrease) in Prepaid Expense and Other Assets, Total
Prepaid expenses and other assets
Increase (Decrease) in Prepaid Expense and Other Assets
Restructuring and Related Activities [Abstract]
Document Fiscal Year Focus
Document Fiscal Year Focus
Revenue, remaining performance obligation, expected timing of satisfaction, period
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period
Investing activities
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Retirement Benefits [Abstract]
Accounts Payable, Current, Total
Accounts payable
Accounts Payable, Current
Research and Development Expense
Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Fair Value Measurements
Fair Value Measurement, Policy [Policy Text Block]
Asset, Held-for-Sale, Not Part of Disposal Group
Asset, Held-for-Sale, Not Part of Disposal Group, Total
Assets as held-for-sale assets
Proceeds from exercise of common stock options
Proceeds from Stock Options Exercised
Fair Value Disclosures [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Lessee, Operating Lease, Liability, to be Paid, Year One
2027
Tasly License Agreement
Tasly License Agreement [Member]
Tasly license agreement.
Share-Based Payment Arrangement [Abstract]
Total unrecognized compensation cost related to unvested granted
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
Materials Supply [Member]
Materials supply.
Materials Supply
Total
Assets, Fair Value Disclosure
Assets, Fair Value Disclosure, Total
Securities held
Equipment and office related expenses
Equipment and office related expenses.
Equipment and office-related expenses
Sale of Stock [Axis]
Collaboration And License Agreements And Supply Agreements [Abstract]
Collaboration and license agreements and supply agreements.
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash used in investing activities
Title of 12(b) Security
Title of 12(b) Security
Schedule of Segment Reporting Information, by Segment [Table]
Weighted - Average Exercise Price, Canceled and forfeited
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Canceled and forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Money Market Funds
Money Market Funds [Member]
Related Party
Related and Nonrelated Parties [Domain]
Income Tax Disclosure [Text Block]
Income Taxes
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
Remaining in 2026
Other Liabilities, Noncurrent, Total
Other Liabilities, Noncurrent
Other non-current liabilities
Restructuring Plan [Domain]
Changes in operating assets and liabilities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Stock options outstanding, Weighted - Average Exercise Price, Beginning Balance
Stock options outstanding, Weighted - Average Exercise Price, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Income Tax Disclosure [Abstract]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value, Recurring and Nonrecurring [Table]
Additional Paid-in Capital
Additional Paid-in Capital [Member]
Stock Issued During Period Shares Through The Underwritten Offering
Stock issued during period shares through the underwritten offering.
Issuance of common stock in connection with underwritten offering, net of issuance costs , Shares
Revenue recognition of up-front payment amount.
Revenue Recognition Of Up Front Payment Amount
Recognition of up front payment
Measurement Frequency
Measurement Frequency [Domain]
Income Statement Location
Statement of Income Location, Balance [Axis]
Trading Symbol
Trading Symbol
Risk-free interest rate, Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Summary of Recognized Revenue
Milestone Method Revenue Recognition Table [Text Block]
Milestone method revenue recognition.
Financing activities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Expected term (in years)
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Supply Agreement
Supply Agreement [Member]
Supply agreement.
Fair Value Measurements Recurring
Fair Value, Recurring [Member]
Entity Ex Transition Period
Entity Ex Transition Period
Total lease payments
Aggregate estimated base rent payments due
Lessee, Operating Lease, Liability, to be Paid
Less: imputed interest
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Unrestricted cash, cash equivalents and marketable securities
Unrestricted Cash Cash Equivalents And Marketable Securities At Carrying Value
Unrestricted cash, cash equivalents and marketable securities at carrying value.
Equity Components
Equity Components [Axis]
Bionova pharmaceuticals, ltd. (bionova).
BioNova Pharmaceuticals, Ltd. (BioNova) [Member]
BioNova Pharmaceuticals, Ltd. ("BioNova")
Nonoperating Income (Expense)
Non-operating loss
Equity Component
Equity Component [Domain]
Asset Class
Asset Class [Axis]
Contingent Payment Earned [Member]
Contingent payment earned.
Contingent Payment Earned
Restructuring Policy [TextBlock]
Restructuring.
Restructuring
Deferred royalty obligation related to the sale of future royalties
Deferred royalty obligation related to the sale of future Vaxcyte royalties, net
Deferred royalty obligation related to the sale of future royalties, classified as noncurrent.
Deferred Royalty Obligation Related To Sale Of Future Royalties, Noncurrent
Vesting of restricted stock units, Shares
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures
Issuance of common stock under Employee Stock Purchase Plan, Shares
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]
Voting rights per share
Common Stock, Voting Rights
Statement of Comprehensive Income [Abstract]
Future Services on Collaboration Joint Steering Committee ("JSC")
Future Services On Collaboration Joint Steering Committee [Member]
Future services on collaboration Joint Steering Committee.
Maximum
Maximum
Maximum [Member]
Statistical Measurement
Statistical Measurement [Axis]
Weighted - Average Exercise Price, Exercised
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Deferred revenue - non-current
Contract with Customer, Liability, Noncurrent
Common Stock, Value, Issued, Ending Balance
Common Stock, Value, Issued, Beginning Balance
Common Stock, Value, Issued, Total
Common Stock, Value, Issued
Common stock value issued
Common stock, $0.001 par value - 300,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 16,576,205 and 8,584,309 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Ongoing Performance Related To Unsatisfied Performance Obligations [Member]
Ongoing performance related to unsatisfied performance obligations.
Ongoing Performance Related to Unsatisfied Performance Obligations
2018 BMS Master Services Agreement
Two Thousand Eighteen BMS Master Services Agreement [Member]
Two thousand eighteen BMS master services agreement.
Increase in stock reserved for issuance as percentage of capital stock outstanding on last day of preceding year
Increase In Stock Reserved For Issuance As Percentage Of Capital Stock Outstanding On Last Day Of Preceding Year
Increase in stock reserved for issuance as percentage of capital stock outstanding on last day of preceding year.
Cash and Cash Equivalents [Abstract]
Royalty [Member]
Royalty
ESPP
Employee Stock Purchase Plan
Employee Stock Purchase Plan [Member]
2018 Employee Stock Purchase Plan.
Cash And Cash Equivalents [Line Items]
Cash and Cash Equivalents [Line Items]
Expected volatility
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Preferred stock shares authorized
Preferred Stock, Shares Authorized
Taxes paid related to net shares settlement of restricted stock units
Payment, Tax Withholding, Share-Based Payment Arrangement
Schedule of Cash Equivalents and Marketable Securities
Cash, Cash Equivalent, and Investment [Table Text Block]
Entity Registrant Name
Entity Registrant Name
Additions to deferred revenue
Contract With Customer Liability Additions
Contract with customer liability additions.
Travel related expenses
Travel related expenses.
Travel-related expenses
Unrealized Losses
Unrealized losses
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Recognition of revenue in current period
Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized
Subsequent Events [Abstract]
Income tax expense
Income Tax Expense (Benefit)
Income Tax Expense (Benefit), Total
Income tax benefits (expense)
Provision for / (benefit) from income taxes
Fair Value Measurements Recurring
Measurement Frequency [Axis]
Proceeds from Issuance of Common Stock
Proceeds from issuance of common stock
Proceeds from sales of common stock, net of issuance costs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Restructuring Impairment And Other Costs Of Deprioritized Program [Member]
Restructuring impairment and other costs of deprioritized program..
Restructuring, and Related Costs
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive loss
Accumulated other comprehensive (loss) income
Consolidation Items [Axis]
Payments for Restructuring
Payments during the period
Payments incurred during the period
Granted
Restricted common stock granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Restrictions on Cash and Cash Equivalents [Table Text Block]
Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash
Gain (Loss), Foreign Currency Transaction, after Tax
Gain (Loss), Foreign Currency Transaction, after Tax, Total
Foreign currency transaction gain (loss)
Total assets
Assets
Weighted - Average Remaining Contract Term, Exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Income Statement [Abstract]
Restructuring Cost [Table]
Cash Equivalents and Marketable Securities
Cash, Cash Equivalent, and Marketable Security [Text Block]
Research And Development Services [Member]
Research and development services.
Research and Development Services
Stock Issued During Period, Shares, New Issues
Issuance of common stock to Ipsen Biopharmaceuticals, Inc. (USA) under the Ipsen Investment Agreement, Shares
Shares of common stock
Vested and released
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Net loss per share, diluted
Net loss per share, diluted
Earnings Per Share, Diluted, Total
Net (loss) income per share, diluted
Summary of Segment Net Loss Including Significant Segment Expenses
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Operating Segment
Operating Segments [Member]
City Area Code
City Area Code
Counterparty Name
Counterparty Name [Domain]
Business Exit Costs
Clinical trial expense and other third-party costs for the deprioritization of the luvelta program
Variable lease cost
Variable Lease, Cost
Issuance of common stock under Employee Stock Purchase Plan
Stock Issued During Period, Value, Employee Stock Purchase Plan
Operating lease, weighted average remaining lease term
Operating Lease, Weighted Average Remaining Lease Term
Segment Reporting Information [Line Items]
Reverse stock split
Stockholders' Equity Note, Stock Split, Conversion Ratio
Total lease costs
Lease, Cost
Laboratory supplies
Laboratory supplies
Laboratory supplies.
Merck Sharp & Dohme Corp
Merck Sharp And Dohme Corporation [Member]
Merck Sharp and Dohme Corporation.
Merck Sharp & Dohme Corporation
Property, Plant and Equipment, Net, Ending Balance
Property, Plant and Equipment, Net, Beginning Balance
Property, Plant and Equipment, Net, Total
Property and equipment, net
Property, Plant and Equipment, Net
Vesting of restricted stock units
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total
Common stock premium
Common Stock, Premium Value
Common stock premium value.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Loss from operations
Operating Income (Loss)
Accumulated Deficit
Retained Earnings [Member]
Non-cash lease expenses
Noncash Lease Expenses
Noncash lease expenses
Cash and Cash Equivalents
Cash and Cash Equivalents [Axis]
Share-based Payment Arrangement, Noncash Expense, Total
Stock-based compensation
Share-Based Payment Arrangement, Noncash Expense
Restricted Stock Units Issued and Outstanding
Restricted Stock Units Issued And Outstanding [Member]
Restricted stock units issued and outstanding.
Liability related to sale of future Vaxcyte royalties - beginning balance
Liability related to the sale of future Vaxcyte royalties - ending balance
Liability Related Sale Of Future Vaxcyte Royalties
Liability Related Sale Of Future Vaxcyte Royalties
CMO
CMO [Member]
CMO.
Total transaction price
Aggregate Transaction Price
Aggregate transaction price.
Operating lease, weighted average discount rate, percent
Operating Lease, Weighted Average Discount Rate, Percent
Operating lease liability - non-current
Total lease liabilities, non-current
Operating lease liabilities non-current
Level 1
Fair Value, Inputs, Level 1 [Member]
Disclosure Text Block [Abstract]
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Net cash provided by financing activities
Schedule of Components of Lease Costs
Lease, Cost [Table Text Block]
Outside services
Outside services
Outside services.
Outside services
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Table]
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Table]
Share based compensation arrangement by share based payment award fair value assumptions and methodology.
U.S. Government Securities
US Government Corporations and Agencies Securities [Member]
Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Corporate Debt Securities
Corporate Debt Securities [Member]
Entity Interactive Data Current
Entity Interactive Data Current
Deferred revenue
Increase (Decrease) in Contract with Customer, Liability
Income Statement Location
Statement of Income Location, Balance [Domain]
Operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Summary of the Status of Call Options
Summary Of Status Of Call Options Table [Text Block]
Summary of status of call options.
Amortization of premium on marketable securities
Accretion (Amortization) of Discounts and Premiums, Investments
Accretion of discount on marketable securities
Secondary Public offering
Secondary Public Offering [Member]
Secondary public offering.
Entity Tax Identification Number
Entity Tax Identification Number
Amended and restated two thousand twenty one equity inducement plan.
Amended And Restated Two Thousand Twenty One Equity Inducement Plan [Member]
Amended and Restated 2021 Equity Inducement Plan
Common stock issuance costs.
Common Stock Issuance Costs
Common stock, issuance costs
Local Phone Number
Local Phone Number
Related Party Transaction
Related Party Transaction [Domain]
Other
Other Liabilities, Current, Total
Other current liabilities
Other Liabilities, Current
Short-term lease cost
Short-Term Lease, Cost
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Denominator:
Restructuring Costs
Restructuring, and related costs
Restructuring and related costs
Total
Restructuring and related costs
Accounting Policies [Abstract]
Summary of Deferred Revenue Balance
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]
Total revenue
Revenue from Contract with Customer, Excluding Assessed Tax, Total
Revenue from Contract with Customer, Excluding Assessed Tax
Revenue
Numerator:
Net Income (Loss) Attributable to Parent [Abstract]
Reimbursements expenses
Reimbursements Expenses
Reimbursements expenses.
Commercial Paper
Commercial Paper [Member]
Labor and Related Expense
Personnel-related expenses
Personnel-related expenses
Shares available for grant
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Remaining unrecognized compensation cost expected to be recognized over weighted-average period
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Entity Emerging Growth Company
Entity Emerging Growth Company